Design Therapeutics to Announce FA Trial Data on May 18, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 58 minutes ago
0mins
Should l Buy DSGN?
Source: Newsfilter
- Trial Data Announcement: Design Therapeutics is set to release data from the ongoing RESTORE-FA trial evaluating DT-216P2 for Friedreich's ataxia patients on May 18, 2026, which is expected to provide critical insights for future treatment strategies.
- Conference Call Details: Management will host a conference call and webcast at 8:00 a.m. ET, aimed at providing investors with a detailed overview of the trial results and their potential implications, thereby boosting market confidence in the company's R&D progress.
- Platform Technology Advantage: Design Therapeutics focuses on developing gene-targeted small molecules based on its GeneTAC® platform, designed to modulate the expression of disease-causing genes, showcasing its innovative potential in the gene therapy space.
- Diverse R&D Pipeline: In addition to DT-216P2, the company is advancing DT-168 for Fuchs endothelial corneal dystrophy and DT-818 for myotonic dystrophy type-1, indicating a broad commitment to addressing multiple genetic diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DSGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DSGN
Wall Street analysts forecast DSGN stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.540
Low
13.00
Averages
15.00
High
18.00
Current: 14.540
Low
13.00
Averages
15.00
High
18.00
About DSGN
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Design Therapeutics to Announce FA Trial Data on May 18, 2026
- Trial Data Announcement: Design Therapeutics is set to release data from the ongoing RESTORE-FA trial evaluating DT-216P2 for Friedreich's ataxia patients on May 18, 2026, which is expected to provide critical insights for future treatment strategies.
- Conference Call Details: Management will host a conference call and webcast at 8:00 a.m. ET, aimed at providing investors with a detailed overview of the trial results and their potential implications, thereby boosting market confidence in the company's R&D progress.
- Platform Technology Advantage: Design Therapeutics focuses on developing gene-targeted small molecules based on its GeneTAC® platform, designed to modulate the expression of disease-causing genes, showcasing its innovative potential in the gene therapy space.
- Diverse R&D Pipeline: In addition to DT-216P2, the company is advancing DT-168 for Fuchs endothelial corneal dystrophy and DT-818 for myotonic dystrophy type-1, indicating a broad commitment to addressing multiple genetic diseases.
See More
Investor Perspectives on Silicon Motion and BillionToOne
- Silicon Motion Outlook: Investors express a positive outlook on Silicon Motion Technology (SIMO), with analysts recommending buying during pullbacks despite significant stock volatility, indicating confidence in its long-term growth potential.
- Wynn's Challenges: Wynn Resorts faces significant investment issues in the Gulf region, and while its stock performance has been strong, management indicates a need to observe developments before making decisions, reflecting a cautious approach to market uncertainties.
- Design Therapeutics Risks: Design Therapeutics is viewed as a high-risk investment, with investors needing to be aware of the potential for total loss, although the potential for doubling returns exists, highlighting the market's high uncertainty regarding its future performance.
- BillionToOne Investment Advice: BillionToOne is favored by investors, with analysts suggesting a buy, indicating optimism about its business model and growth prospects, which may attract more investor attention.
See More
RESTORE-FA Trial Progressing Well with Promising Data Expected
- Trial Progress: The RESTORE-FA trial is progressing well, with data expected in the second half of 2026, aiming to provide a go/no-go decision for the FA program and establish clinical proof of concept to inform future regulatory pathways.
- Biomarker Evaluation: The study is evaluating endogenous frataxin levels in both blood and muscle, focusing on mRNA and protein to identify a potential primary surrogate biomarker that could reasonably predict clinical benefit.
- Mechanism of DT216: DT216 is a heterobifunctional gene-targeted chimera designed to recognize long GA repeat expansions and increase normal frataxin RNA transcription, with cellular data suggesting that 10 nanomolar levels may be sufficient to increase frataxin with adequate exposure duration.
- Dosing Structure: The dosing structure of the RESTORE-FA study began with escalations from 0.1 mg/kg to 0.6 mg/kg over four weeks, and a 1 mg/kg group has been initiated, incorporating 12-week treatment cohorts to generate additional exposure and data.
See More
Design Therapeutics Reports Q1 2026 Financial Results and Milestones
- Improved Financial Performance: In Q1 2026, Design Therapeutics reported a net loss of $17.64 million, or $0.29 per share, down from $17.72 million and $0.31 per share in the previous year, indicating positive progress in cost control and operational efficiency.
- Strong Cash Position: As of March 31, 2026, the company had $222.8 million in cash, cash equivalents, and investment securities, which is expected to fund operations into 2029, enhancing investor confidence in the company's long-term growth prospects.
- Clinical Trial Progress: The ongoing RESTORE-FA trial for DT-216P2 in Friedreich's Ataxia patients is evaluating multiple ascending doses, with an update on its effect on endogenous frataxin levels anticipated in the second half of 2026, potentially offering new hope for treatment.
- New Project Launch: In the Myotonic Dystrophy Type-1 (DM1) program, Design Therapeutics plans to initiate dosing of DM1 patients in the Phase 1 multiple-ascending dose trial for DT-818 in the first half of 2026, marking further expansion in the gene therapy space.
See More
Design Therapeutics Q4 Earnings Beat Expectations
- Earnings Performance: Design Therapeutics reported a Q4 GAAP EPS of -$0.27, beating market expectations of -$0.37, indicating improvements in financial management and operational efficiency.
- Strong Cash Reserves: As of December 31, 2025, the company held $219.8 million in cash, cash equivalents, and investment securities, which is expected to fund its operations through 2029, bolstering investor confidence in its long-term viability.
- Increased Market Attention: The release of the earnings report has heightened interest in Design Therapeutics, with its Quant Rating on Seeking Alpha drawing significant attention, potentially attracting more investors and driving stock price appreciation.
- Historical Financial Data Insights: The ongoing improvement in the company's historical financial data suggests that Design Therapeutics is gradually achieving its business objectives, positioning itself for a stronger market presence in the biopharmaceutical sector.
See More
FibroBiologics (FBLG) Stock Rises 7.68%, Attracts Market Attention
- FibroBiologics Outperformance: FibroBiologics, Inc. (FBLG) surged 7.68% in after-hours trading to close at $0.41, indicating speculative interest or technical momentum despite no specific news.
- Nyxoah Earnings Boost Confidence: Nyxoah SA (NYXH) advanced 3.94% to $5.28 after reporting preliminary Q4 and full-year 2025 results, with guidance for Q1 2026 enhancing investor confidence in its growth trajectory.
- Fortress Biotech's Continued Volatility: Fortress Biotech, Inc. (FBIO) climbed 6.90% to $4.49 in after-hours trading, continuing a trend of volatility without any fresh news impacting the stock.
- Revvity Collaboration Drives Growth: Revvity, Inc. (RVTY) posted a 4.92% gain to close at $109.00, as investors digest the January announcement of a collaboration with Eli Lilly to expand access to predictive models via the Revvity Signals platform.
See More
Design Therapeutics to Announce FA Trial Data on May 18, 2026
- Trial Data Announcement: Design Therapeutics is set to release data from the ongoing RESTORE-FA trial evaluating DT-216P2 for Friedreich's ataxia patients on May 18, 2026, which is expected to provide critical insights for future treatment strategies.
- Conference Call Details: Management will host a conference call and webcast at 8:00 a.m. ET, aimed at providing investors with a detailed overview of the trial results and their potential implications, thereby boosting market confidence in the company's R&D progress.
- Platform Technology Advantage: Design Therapeutics focuses on developing gene-targeted small molecules based on its GeneTAC® platform, designed to modulate the expression of disease-causing genes, showcasing its innovative potential in the gene therapy space.
- Diverse R&D Pipeline: In addition to DT-216P2, the company is advancing DT-168 for Fuchs endothelial corneal dystrophy and DT-818 for myotonic dystrophy type-1, indicating a broad commitment to addressing multiple genetic diseases.
See More
Investor Perspectives on Silicon Motion and BillionToOne
- Silicon Motion Outlook: Investors express a positive outlook on Silicon Motion Technology (SIMO), with analysts recommending buying during pullbacks despite significant stock volatility, indicating confidence in its long-term growth potential.
- Wynn's Challenges: Wynn Resorts faces significant investment issues in the Gulf region, and while its stock performance has been strong, management indicates a need to observe developments before making decisions, reflecting a cautious approach to market uncertainties.
- Design Therapeutics Risks: Design Therapeutics is viewed as a high-risk investment, with investors needing to be aware of the potential for total loss, although the potential for doubling returns exists, highlighting the market's high uncertainty regarding its future performance.
- BillionToOne Investment Advice: BillionToOne is favored by investors, with analysts suggesting a buy, indicating optimism about its business model and growth prospects, which may attract more investor attention.
See More
RESTORE-FA Trial Progressing Well with Promising Data Expected
- Trial Progress: The RESTORE-FA trial is progressing well, with data expected in the second half of 2026, aiming to provide a go/no-go decision for the FA program and establish clinical proof of concept to inform future regulatory pathways.
- Biomarker Evaluation: The study is evaluating endogenous frataxin levels in both blood and muscle, focusing on mRNA and protein to identify a potential primary surrogate biomarker that could reasonably predict clinical benefit.
- Mechanism of DT216: DT216 is a heterobifunctional gene-targeted chimera designed to recognize long GA repeat expansions and increase normal frataxin RNA transcription, with cellular data suggesting that 10 nanomolar levels may be sufficient to increase frataxin with adequate exposure duration.
- Dosing Structure: The dosing structure of the RESTORE-FA study began with escalations from 0.1 mg/kg to 0.6 mg/kg over four weeks, and a 1 mg/kg group has been initiated, incorporating 12-week treatment cohorts to generate additional exposure and data.
See More
Design Therapeutics Reports Q1 2026 Financial Results and Milestones
- Improved Financial Performance: In Q1 2026, Design Therapeutics reported a net loss of $17.64 million, or $0.29 per share, down from $17.72 million and $0.31 per share in the previous year, indicating positive progress in cost control and operational efficiency.
- Strong Cash Position: As of March 31, 2026, the company had $222.8 million in cash, cash equivalents, and investment securities, which is expected to fund operations into 2029, enhancing investor confidence in the company's long-term growth prospects.
- Clinical Trial Progress: The ongoing RESTORE-FA trial for DT-216P2 in Friedreich's Ataxia patients is evaluating multiple ascending doses, with an update on its effect on endogenous frataxin levels anticipated in the second half of 2026, potentially offering new hope for treatment.
- New Project Launch: In the Myotonic Dystrophy Type-1 (DM1) program, Design Therapeutics plans to initiate dosing of DM1 patients in the Phase 1 multiple-ascending dose trial for DT-818 in the first half of 2026, marking further expansion in the gene therapy space.
See More
Design Therapeutics Q4 Earnings Beat Expectations
- Earnings Performance: Design Therapeutics reported a Q4 GAAP EPS of -$0.27, beating market expectations of -$0.37, indicating improvements in financial management and operational efficiency.
- Strong Cash Reserves: As of December 31, 2025, the company held $219.8 million in cash, cash equivalents, and investment securities, which is expected to fund its operations through 2029, bolstering investor confidence in its long-term viability.
- Increased Market Attention: The release of the earnings report has heightened interest in Design Therapeutics, with its Quant Rating on Seeking Alpha drawing significant attention, potentially attracting more investors and driving stock price appreciation.
- Historical Financial Data Insights: The ongoing improvement in the company's historical financial data suggests that Design Therapeutics is gradually achieving its business objectives, positioning itself for a stronger market presence in the biopharmaceutical sector.
See More
FibroBiologics (FBLG) Stock Rises 7.68%, Attracts Market Attention
- FibroBiologics Outperformance: FibroBiologics, Inc. (FBLG) surged 7.68% in after-hours trading to close at $0.41, indicating speculative interest or technical momentum despite no specific news.
- Nyxoah Earnings Boost Confidence: Nyxoah SA (NYXH) advanced 3.94% to $5.28 after reporting preliminary Q4 and full-year 2025 results, with guidance for Q1 2026 enhancing investor confidence in its growth trajectory.
- Fortress Biotech's Continued Volatility: Fortress Biotech, Inc. (FBIO) climbed 6.90% to $4.49 in after-hours trading, continuing a trend of volatility without any fresh news impacting the stock.
- Revvity Collaboration Drives Growth: Revvity, Inc. (RVTY) posted a 4.92% gain to close at $109.00, as investors digest the January announcement of a collaboration with Eli Lilly to expand access to predictive models via the Revvity Signals platform.
See More
